Beigene Stock Performance
| BGNE Stock | USD 206.16 14.05 7.31% |
BeiGene has a performance score of 5 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.18, which signifies not very significant fluctuations relative to the market. As returns on the market increase, BeiGene's returns are expected to increase less than the market. However, during the bear market, the loss of holding BeiGene is expected to be smaller as well. BeiGene right now shows a risk of 2.59%. Please confirm BeiGene value at risk, kurtosis, and the relationship between the sortino ratio and semi variance , to decide if BeiGene will be following its price patterns.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in BeiGene are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady basic indicators, BeiGene may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Actual Historical Performance (%)
One Day Return 7.31 | Five Day Return 7.97 | Year To Date Return 16.47 | Ten Year Return 627.97 | All Time Return 627.97 |
1 | Disposition of 1202 shares by Chan Lee of BeiGene at 237.1 subject to Rule 16b-3 | 09/30/2024 |
2 | Disposition of 1452 shares by John Oyler of BeiGene at 236.3695 subject to Rule 16b-3 | 10/08/2024 |
3 | Disposition of 428 shares by John Oyler of BeiGene at 234.2728 subject to Rule 16b-3 | 10/18/2024 |
4 | BeiGene erhlt positive CHMP-Stellungnahmen zu TEVIMBRA als Erstlinienbehandlung bei fortgeschrittenemmetastasierendem Magenkrebs oder Krebs des gastrosophageale... | 10/22/2024 |
5 | Earnings call Zymeworks reports Q3 2024 results and pipeline progress | 11/01/2024 |
6 | BeiGene destaca su innovador dosier de hematologa en neoplasias malignas de clulas B en la conferencia de la American Society of Hematology de 2024 | 11/08/2024 |
7 | Riassunto BeiGene annuncia i risultati finanziari del terzo trimestre 2024 e gli aggiornamenti aziendali | 11/13/2024 |
8 | BeiGene Third Quarter 2024 Earnings Revenues Beat Expectations, EPS Lags | 11/14/2024 |
9 | BeiGene revela proposta de mudana de nome para BeOne Medicines, reafirmando sua misso de unir a comunidade global contra o cncer | 11/15/2024 |
10 | BeiGene settles patent litigation, extends BRUKINSA exclusivity | 11/19/2024 |
| Begin Period Cash Flow | 3.9 B |
BeiGene |
BeiGene Relative Risk vs. Return Landscape
If you would invest 18,826 in BeiGene on August 31, 2024 and sell it today you would earn a total of 1,790 from holding BeiGene or generate 9.51% return on investment over 90 days. BeiGene is currently generating 0.1773% in daily expected returns and assumes 2.5915% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than BeiGene, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BeiGene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BeiGene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BeiGene, and traders can use it to determine the average amount a BeiGene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0684
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BGNE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.59 actual daily | 23 77% of assets are more volatile |
Expected Return
| 0.18 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average BeiGene is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BeiGene by adding it to a well-diversified portfolio.
BeiGene Fundamentals Growth
BeiGene Stock prices reflect investors' perceptions of the future prospects and financial health of BeiGene, and BeiGene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BeiGene Stock performance.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0958 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 21.04 B | ||||
| Shares Outstanding | 97.43 M | ||||
| Price To Earning | (16.19) X | ||||
| Price To Book | 6.38 X | ||||
| Price To Sales | 0.96 X | ||||
| Revenue | 2.46 B | ||||
| Gross Profit | (511.06 M) | ||||
| EBITDA | (1.12 B) | ||||
| Net Income | (881.71 M) | ||||
| Cash And Equivalents | 5.7 B | ||||
| Cash Per Share | 55.17 X | ||||
| Total Debt | 930.18 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 4.54 X | ||||
| Book Value Per Share | 226.72 X | ||||
| Cash Flow From Operations | (1.16 B) | ||||
| Earnings Per Share | (8.18) X | ||||
| Market Capitalization | 22.64 B | ||||
| Total Asset | 5.81 B | ||||
| Retained Earnings | (7.96 B) | ||||
| Working Capital | 2.39 B | ||||
| Current Asset | 106.27 M | ||||
| Current Liabilities | 35.17 M | ||||
About BeiGene Performance
By analyzing BeiGene's fundamental ratios, stakeholders can gain valuable insights into BeiGene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BeiGene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BeiGene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 399.78 | 419.77 | |
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.30) | (0.32) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.25) | (0.26) |
Things to note about BeiGene performance evaluation
Checking the ongoing alerts about BeiGene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BeiGene help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 2.46 B. Net Loss for the year was (881.71 M) with loss before overhead, payroll, taxes, and interest of (511.06 M). | |
| BeiGene currently holds about 5.7 B in cash with (1.16 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 55.17. | |
| Roughly 19.0% of the company shares are held by company insiders | |
| Latest headline from investing.com: BeiGene settles patent litigation, extends BRUKINSA exclusivity |
- Analyzing BeiGene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BeiGene's stock is overvalued or undervalued compared to its peers.
- Examining BeiGene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BeiGene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BeiGene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BeiGene's stock. These opinions can provide insight into BeiGene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |